Revolutionise treatment of our biggest killer - heart disease!

By Dr Steven Wise, The Heart Research Institute

Campaign Completed on

{{ shares.facebook | thousands }}

Total shares

The Problem

Heart disease is the single biggest killer.

Around 1 in every 3 deaths is due to heart disease.

The problem with existing treatments for heart disease (and other diseases) is that they can't be targeted to specific parts of the body, like the heart muscle.

As a result, these treatments can be a toxic assault on the body, often leaving patients with long-term side effects.

Why does this happen? Because under current delivery methods, drugs cannot be targeted directly to the affected area. Other parts of the body are exposed, reducing the amount of medicine reaching the part of the body where it is needed the most to fight the disease.

This means a higher dosage of the drug is often required and healthy cells can be damaged during treatment.

If we could deliver the drug directly to the diseased part of the body,  we could more effectively treat the disease, minimise side effects and improve the quality of life for patients.

We desperately need more effective treatments to fight heart disease and save lives.

The Solution

The Heart Research Institute has made a groundbreaking discovery – a new type of nanoparticle that can deliver highly targeted treatment to a specific part of the body to fight heart disease.

Why are these nanoparticles so revolutionary?

In Dr Miguel Santos' words:

"If you think of a conventional therapy like chemotherapy as a blind cyclist trying to find his way, then our newly discovered nanoparticle is like a truck. And not just any truck, but one with heavy haulage capabilities and powerful GPS tracking.  

"Our nanoparticle has the potential to deliver large quantities of the drug to exactly where it needs to go and nowhere else."

For more information, watch this clip:

Unlike current treatments, our nanoparticles target only disease-affected cells and can be customised to the exact health needs of the individual.

Example: For a patient with failing heart muscle, we can deliver tailored treatments directly to the part of the muscle affected.

This kind of GPS-style precision means much smaller drug quantities are needed and the frequency of treatment is greatly reduced.

It also means much safer, less toxic treatments, with reduced side effects for patients.

This groundbreaking nanomedicine would be vastly more efficient than existing conventional treatments.

Next Step: Build a Plasma Reactor

Our scientists have developed a lab prototype and blueprint of a custom-made machine - a Plasma Reactor - to make this newly discovered type of nanoparticle. 

And we need to raise $80,000 by 17th December 2018 to buy the vital parts to build this state of the art plasma reactor.

Image showing the plasma reactor prototype and the breakthrough plasma nanoparticles interacting with cells.

Not only could this plasma reactor revolutionise the treatment of heart disease through highly targeted nanomedicine, but it would also be a game-changer for the treatment of cancer, Alzheimer's, genetic diseases, and every other major disease of our lifetime.

The potential applications of this nanotechnology are limitless.

How You Can Help

Buy a part and help to build a world-first plasma reactor to revolutionise the fight against heart disease.

  • $25 – Heart Supporter – Buy 1 part of the plasma reactor
  • $50 – Heart Builder – Buy 2 parts of the plasma reactor
  • $100 – Heart Innovator – Buy 4 parts of the plasma reactor
  • $500 – Heart Leader – Will fund a vital chamber of the plasma reactor
  • $2,000 – Heart Pioneer – Will help to fund and assemble several parts of the plasma reactor

We need to raise $80,000 to buy all the parts and build the plasma reactor so we can start manufacturing nanoparticles in the laboratory by early 2019.

About The Heart Research Institute

The Heart Research Institute is a world-class medical research institute and a hub for scientific excellence in heart research. Our scientists are focused on understanding the causes and complications of heart disease and are at the forefront of conducting innovative research to prevent, detect and treat Australia's number one killer – heart disease. 

Giving from outside Australia?

HRI supporters are located across the globe, helping to drive change and making a difference to the lives of many by donating to the research projects at HRI. HRI advises that donations cannot be accepted from any person in a country where it is unlawful to do so.

Below are details on how some of our overseas supporters can benefit from making gifts to the Heart Research Institute.

Donating from the UK

The HRI offers an additional opportunity to maximise the impact of your gift. By donating to the HRI UK, and if you are a UK taxpayer, you enable Gift Aid to be claimed from the UK Government and added to your initial gift amount. You may also be entitled to claim higher rate tax relief. This means a minimum of 25% extra will be added to your gift, the combined total of which is available to the HRI UK.

The Heart Research Institute (UK) is a registered charity No. 1116918 (England and Wales) and SC042984 (Scotland)

For more information, please visit our Privacy Policy at

Donating from Canada

The Heart Research Institute (Canada) is registered with number: 83580 6936 RR0001

Donating from New Zealand

The Heart Research Institute (NZ) Limited is registered under the Charities Act 2005 - CC: 48711

This campaign is run by The Heart Research Institute Limited and its wholly owned entities. Contributions do not constitute a legal right or share of ownership in the machine or project. HRI will review naming votes and decide on the final name in its sole discretion. Any cost to visit the HRI facility in Newtown, NSW for a lab tour will be at the contributors own expense.

    {{ giver.full_name}}

    {{ giver.created_at }}
    {{ currencyConversion(giver.currency) }}

    ${{ currencyConversion(giver.currency) }}{{ giver.don_amount }}

    Offline donation

Team Members

Dr Steven Wise, The Heart Research Institute